Search Medical Condition
Please enter condition
Please choose location from dropdown

Epsom, United Kingdom Clinical Trials

A listing of Epsom, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (149) clinical trials

Optimising Renal Outcome in Myeloma Renal Failure

Renal impairment is a life threatening condition of myeloma. 20-25% of patients will present at diagnosis with renal dysfunction. Outcome is poor due to high early mortality, with 28% of newly diagnosed myeloma patients in myeloma trials with renal failure not surviving beyond 100 days, compared with 10% overall. This ...

Phase

0.0 miles

Learn More »

Fludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untreated Mantle Cell Lymphoma

OBJECTIVES: Primary - To determine the overall survival in patients with untreated mantle cell lymphoma treated with fludarabine phosphate and cyclophosphamide with vs without rituximab. Secondary - To determine the progression-free survival in patients treated with this regimen. - To determine the toxicity of this regimen in these patients. - ...

Phase

0.8 miles

Learn More »

The Medacta International GMK Sphere Post-Marketing Surveillance Study

This is a Post-Marketing Surveillance of GMK Sphere knee prosthesis.

Phase N/A

0.8 miles

Learn More »

The Medacta International SMS Post-Marketing Surveillance Study

This is a Post-Marketing Surveillance of SMS femoral stem prosthesis.

Phase N/A

0.8 miles

Learn More »

AZD8186 First Time In Patient Ascending Dose Study

This is a phase I, open-label, multicentre study of AZD8186 administered orally in patients with advanced castrate-resistant prostate cancer (CRPC), squamous non-small cell lung cancer (sqNSCLC), triple negative breast cancer (TNBC) and known PTEN-deficient/mutated or PIK3CB mutated/amplified advanced solid malignancies. The study design allows an escalation of dose with intensive ...

Phase

2.95 miles

Learn More »

An Investigation of TAS-119 Monotherapy and in Combination With Docetaxel

This is a Phase 1, open-label, non-randomized, dose escalation study of TAS-119 evaluating the safety, tolerability, PK, pharmacogenomics, pharmacodynamics, and preliminary antitumour activity in patients with advanced and unresectable solid tumours. The study will evaluate TAS-119 monotherapy, employing two sequential phases. A Dose Escalation Phase An Expansion Phase

Phase

3.22 miles

Learn More »

Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

This is a first in human, multinational, phase 1, open-label study of TAS3681 in patients with metastatic castration resistant prostate cancer (mCRPC)evaluating safety, tolerability, pharmacokinetics and preliminary antitumor activity in patients with mCRPC for which there is no standard therapy. Eligible patients will either be enrolled in the dose escalation ...

Phase

3.22 miles

Learn More »

A Safety Study to Determine Dose and Tolerability of CC-220 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Subjects assigned to CC-220 monotherapy, who develop PD will have the option to receive DEX in addition to CC-220 after consultation with the Medical Monitor. The dose of CC-220 will not be higher than the dose of CC-220 used in combination with dexamethasone in Cohort B that has been determined ...

Phase

3.22 miles

Learn More »

Study of Lorlatinib (PF-06463922)

Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. An adult phase 1 study established an RP2D of 100mg QD for lorlatinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and in combination with chemotherapy in ...

Phase

3.22 miles

Learn More »

Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

This is a prospective, open label, multicentre, randomised phase II clinical trial. An adaptive trial design is proposed to allow ineffective treatments to be discontinued early, and to potentially add novel treatment arms as the trial progresses. Patients will initially receive standard chemotherapy for their locally advanced or metastatic oesophago-gastric ...

Phase

3.24 miles

Learn More »